Literature DB >> 22082991

Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC).

D F Kolomainen1, A Daponte, D P J Barton, K Pennert, T E J Ind, J E Bridges, J H Shepherd, M E Gore, S B Kaye, J Riley.   

Abstract

OBJECTIVE: To describe the outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) so as to define the criteria for patient selection for palliative surgery.
METHODS: 90 women with relapsed EOC underwent palliative surgery for bowel obstruction between 1992 and 2008.
RESULTS: Median age at time of surgery for bowel obstruction was 57 years (range, 26 to 85 years). All patients had received at least one line of platinum-based chemotherapy. Median time from diagnosis of primary disease to documented bowel obstruction requiring surgery was 19.5 months (range, 29 days-14 years). Median interval from date of completed course of chemotherapy preceding surgery for bowel obstruction was 3.8 months (range, 5 days-14 years). Ascites was present in 38/90(42%). 49/90(54%) underwent emergency surgery for bowel obstruction. The operative mortality and morbidity rates were 18% and 27%, respectively. Successful palliation, defined as adequate oral intake at least 60 days postoperative, was achieved in 59/90(66%). Only the absence of ascites was identified as a predictor for successful palliation (p=0.049). The median overall survival (OS) was 90.5 days (range, <1 day-6 years). Optimal debulking, treatment-free interval (TFI) and elective versus emergency surgery did not predict survival or successful palliation from surgery for bowel obstruction (p>0.05).
CONCLUSION: Surgery for bowel obstruction in relapsed EOC is associated with a high morbidity and mortality rate especially in emergency cases when compared to other gynaecological oncological procedures. Palliation can be achieved in almost two thirds of cases, is equally likely in elective and emergency cases but is less likely in those with ascites. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22082991     DOI: 10.1016/j.ygyno.2011.11.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

Review 1.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  Sarah E Cousins; Emma Tempest; David J Feuer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

2.  Palliative care in patients with ovarian cancer and bowel obstruction.

Authors:  Alberto Daniele; A Ferrero; L Fuso; M Mineccia; V Porcellana; D Vassallo; N Biglia; G Menato
Journal:  Support Care Cancer       Date:  2015-03-25       Impact factor: 3.603

Review 3.  The role of parenteral nutrition in patients with malignant bowel obstruction.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2019-07-17       Impact factor: 3.603

4.  Non-Surgical Management of Malignant Bowel Obstruction in Advanced Ovarian Cancer patients: A Systematic Review and Meta-Analysis.

Authors:  Praveena Idaikkadar; Athina Georgiou; Simon Skene; Agnieszka Michael
Journal:  Am J Hosp Palliat Care       Date:  2021-09-07       Impact factor: 2.090

Review 5.  Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review.

Authors:  Terrah J Paul Olson; Carolyn Pinkerton; Karen J Brasel; Margaret L Schwarze
Journal:  JAMA Surg       Date:  2014-04       Impact factor: 14.766

6.  Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.

Authors:  K S Rath; D Loseth; P Muscarella; G S Phillips; J M Fowler; D M O'Malley; D E Cohn; L J Copeland; E L Eisenhauer; R Salani
Journal:  Gynecol Oncol       Date:  2013-01-29       Impact factor: 5.482

Review 7.  Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.

Authors:  Yeh Chen Lee; Nazlin Jivraj; Catherine O'Brien; Tanya Chawla; Eran Shlomovitz; Sarah Buchanan; Jenny Lau; Jennifer Croke; Johane P Allard; Preeti Dhar; Stephane Laframboise; Sarah E Ferguson; Neesha Dhani; Marcus Butler; Pamela Ng; Terri Stuart-McEwan; Pamela Savage; Lisa Tinker; Amit M Oza; Stephanie Lheureux
Journal:  Obstet Gynecol Int       Date:  2018-05-17

8.  Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer.

Authors:  Robert D Morgan; Sofia Stamatopoulou; Nerissa Mescallado; Geoff Saunders; Richard Welch; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson
Journal:  ESMO Open       Date:  2019-03-21

Review 9.  Ovarian Cancer Dissemination-A Cell Biologist's Perspective.

Authors:  Sadaf Farsinejad; Thomas Cattabiani; Taru Muranen; Marcin Iwanicki
Journal:  Cancers (Basel)       Date:  2019-12-06       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.